Roche (SIX:RO, ROG; OTCQX:RHHBY) has announced new positive two-year data from its TENAYA and LUCERNE studies of Vabysmo (faricimab) in neovascular or “wet” age-related macular degeneration (nAMD). Based on the study results, Roche estimates that more than 60% of people taking the drug could receive an injection of facrimab once every four months while achieving…

New macular degeneration treatments could offer superior durability to current anti-vascular endothelial growth factor therapy (anti-VEGF). But new drugs must have a similar safety profile to existing therapies to be competitive, according to a UBS briefing note.  The macular degeneration treatment landscape changed significantly in 2005 when FDA approved Macugen (pegaptanib sodium injection) from Pfizer (NYSE:PFE) to…